Methods In this randomised, double-blind, placebo-controlled trial, we enrolled 2507 women in the second or third trimester of pregnancy who were planning to deliver in Entebbe General Hospital, Entebbe, Uganda. With a computergenerated random number sequence in blocks of 100, we assigned patients to 440 mg albendazole and 40 mg/kg praziquantel (n=628), 440 mg albendazole and a praziquantel-matching placebo (n=625), 40 mg/kg praziquantel and an albendazole-matching placebo (n=626), or an albendazole-matching placebo and praziquantel-matching placebo (n=628). All participants and hospital staff were masked to allocation. Primary outcomes were immune response at age 1 year to BCG, tetanus, and measles immunisation; incidence of infectious diseases during infancy; and vertical HIV transmission. Analysis was by intention-to-treat. This trial is registered, number ISRCTN32849447.
Introduction
Worldwide, infectious diseases account for more than 50% of deaths of children younger than 5 years; pneumonia, diarrhoeal disease, and malaria are the three most common causes. 1 More than half of these deaths occur in sub-Saharan Africa, where roughly 2·5 million children younger than 5 years are estimated to die every year from one of these three diseases. Immunisation is a key strategy to combat infectious diseases, but immunisation programmes in developing countries vary in eff ectiveness. 2 For example, increases in measles immunisation coverage have led to substantial falls in the incidence of measles; 3 by contrast, despite high immunisation coverage, the prevalence of tuberculosis is high in sub-Saharan Africa, and is one of the leading causes of deaths in adults. 4 BCG is the only available vaccine against tuberculosis and its eff ectiveness is lowest in countries closest to the equator. 5, 6 Soiltransmitted helminth infections and schistosomiasis are also prevalent in developing countries, 7 and their geographical distribution has extensive overlap with areas in which rates of infectious diseases are highest and the eff ectiveness of BCG immunisation is lowest. 8, 9 Such overlap in disease distributions has led to the suggestion that chronic helminth infections could aff ect the epidemiological patterns of other diseases, 10 through impairment of immune responses to immunisations and unrelated infections.
This hypothesis was supported by the fi nding that T-helper-1 (Th1) cell responses (characterised by interferon-γ production, induced by viral and bacterial antigens, and required for protection against mycobacteria and other intracellular pathogens) and T-helper-2 (Th2) cell responses (characterised by production of interleukins 4, 5, and 13 and induced by allergens such as helminth antigens) are mutually inhibitory. [11] [12] [13] However, helminth infections induce immunoregulation by various other mechanisms, such as interleukin-10 production, and aff ect responses to non-helminth antigens. 14 Thus helminth infections could inhibit protective Th1 responses to unrelated organisms, such as viruses, bacteria, and vaccines, by inducing a Th1 to Th2 switch and through immunoregulatory mechanisms. Several studies of animals and human beings lend support to this hypothesis. 14 Although helminth infections are generally thought to have detrimental eff ects on host responses to infectious pathogens, a benefi cial eff ect against other diseases is also possible through suppression of pathological infl ammatory responses; some researchers have suggested an inverse association between helminth infections and incidence of severe malaria. 15 Helminth infections are rare in infancy, when immunisations are given and many infectious diseaserelated deaths occur. However, evidence exists that prenatal exposure to maternal helminth infection could have important eff ects on an infant's immune response. Prenatal sensitisation to Wuchereria bancrofti, a fi larial worm, is associated with increased susceptibility to W bancrofti infection in childhood, 16 and prenatal sensitisation to fi larial or schistosome antigens with reduced Th1 and increased Th2 cytokine responses to mycobacterial antigens after BCG immunisation at birth. 2, 17 Such fi ndings suggest that prenatal exposure to maternal helminth infection modulates an infant's immune response to vaccination and infectious pathogens, and that anthelmintic treatment during pregnancy can prevent these eff ects. We designed this trial of anthelmintic treatment during pregnancy to address this hypothesis. We also examined eff ects of anthelmintic treatment during pregnancy on infant mortality, and on anaemia and growth at age 1 year, to assess the overall risks and benefi ts of anthelmintic treatment during pregnancy.
Methods

Study design and patients
The study is described in detail elsewhere. 18 Briefl y, the study area was Entebbe Municipality and Katabi subcounty, beside Lake Victoria, Uganda. The area is occupied by urban, rural, and fi shing communities. Helminth infection is highly prevalent in the area, 19 and malaria, diarrhoea, and pneumonia are common in young children. 20 The study population consisted of pregnant women who presented at the governmentfunded antenatal clinic at Entebbe General Hospital between April 9, 2003, and Nov 24, 2005 , where roughly 70% of pregnant women from the study area received antenatal care. 21 Women were included if resident in the study area, planning to deliver in the hospital, willing to know their HIV status, and in the second or third trimester of pregnancy. They were excluded if they had possible helminth-induced pathological changes (haemoglobin <80 g/L, clinically apparent severe liver disease, or diarrhoea with blood in stool), a history of an adverse reaction to anthelmintics, already been enrolled in the trial during an earlier pregnancy, or if the pregnancy was deemed abnormal by a midwife.
All participants gave written, informed consent. Ethics approval was given by the Uganda Virus Research Institute, Uganda National Council for Science and Technology, and London School of Hygiene and Tropical Medicine.
Randomisation and masking
We used a two-by-two factorial design to randomly assign patients in a 1:1:1:1 ratio to receive simultaneously either single-dose albendazole (440 mg) and single-dose praziquantel (40 mg/kg), albendazole and a praziquantelmatching placebo, an albendazole-matching placebo and praziquantel, or an albendazole-matching placebo and a praziquantel-matching placebo (albendazole and matching placebo, Glaxosmithkline, Brentford, UK; praziquantel and matching placebo, Medochemie Ltd, Limassal, Cyprus). The randomisation code was generated by the trial statistician with a computergenerated random number sequence, with block size 100. Treatments were packed in sealed envelopes and labelled with an allocation number by colleagues at the Medical Research Council Unit in Entebbe who did not otherwise contribute to the trial. Treatments were allocated in numerical order by trained interviewer-counsellors who observed the patients taking the treatment correctly on enrolment to the study. Treatment allocation was masked from all participants and staff during the study.
Procedures
Demographic and clinical details, and blood samples were obtained at screening; stool samples were obtained before enrolment. After enrolment, women continued to receive standard antenatal care, including haematinics, tetanus immunisation, and intermittent presumptive treatment for malaria twice after their fi rst trimester of pregnancy; women with HIV were off ered intrapartum and neonatal single-dose nevirapine for prevention of mother-to-child (vertical) HIV transmission. 22 Stool samples were obtained after delivery to assess eff ectiveness of anthelmintic treatment; thereafter, all mothers received praziquantel and albendazole. Infants received BCG and polio immunisation at birth; diphtheria, pertussis, tetanus, Haemophilus infl uenzae, hepatitis B, and polio immunisation at 6, 10, and 14 weeks; and measles immunisation at 9 months. Children also attended the study clinic when unwell; doctors diagnosed, treated, and recorded their illnesses. Community fi eldworkers visited each participant's home twice a month, measured the child's temperature, and recorded symptoms reported by the child's carer. At age 12 months, blood and stool samples were obtained from the children and growth outcomes were measured. Children who were unwell at their 12-month visit were given appropriate treatment and asked to return to complete the visit procedures when well.
The primary outcomes were immune response at age 1 year to BCG, tetanus, and measles immunisation; incidence of malaria, diarrhoea, pneumonia, measles, and tuberculosis during infancy as diagnosed by doctors at the study clinic; and vertical HIV transmission. 18 Planned secondary outcomes were growth and anaemia at age 1 year. Community-reported data for illness events were included as a secondary outcome for comparison with doctor-diagnosed illness events from clinic visits. We also considered two additional unplanned secondary outcomes: infant mortality and asymptomatic malaria (presence of malaria parasitaemia) at 1 year of age.
Cytokine responses at 1 year of age to crude culture fi ltrate proteins of Mycobacterium tuberculosis (cCFP) were measured as an indicator of response to BCG immunisation. Cytokine responses at age 1 year to tetanus toxoid were measured as an indicator of response to tetanus immunisation. We examined stimulated interferon-γ (type 1), interleukin-5 (type 2), interleukin-13 (type 2), and interleukin-10 (regulatory) responses in a whole-blood assay, as previously described. 23 Total serum IgG, IgG4, and IgE responses to tetanus toxoid were measured by ELISA (webappendix p 1).
Total serum measles-specifi c IgG was measured by ELISA (Dade Behring/Siemens, Eschborn, Germany) according to the manufacturer's protocol. Immunological assays were done after all samples had been obtained, in a randomised sequence (by use of a computer-generated random number sequence), to avoid confounding of secular trends with variations in assay performance.
For the primary outcome, doctor-diagnosed illness events, clinical malaria was fever (temperature ≥37·5°C) with parasitaemia; diarrhoea was an infant's carer's defi nition, with stool frequency recorded; 24 pneumonia was cough with diffi culty in breathing, and age-specifi c fast breathing; 25 measles was defi ned by standard clinical criteria and confi rmed by measurement of specifi c antibody; 26 and children with suspected tuberculosis were investigated as clinically indicated. 27 For the secondary outcome, community-reported illnesses, febrile illness was defi ned as measured by fi eldworkers (temperature ≥37·5°C) or as reported by the child's carer; diarrhoea as reported by the carer, with stool frequency recorded; presumptive pneumonia was cough with diffi culty in breathing, or age-specifi c fast breathing as measured by fi eldworkers.
Stool samples were examined for helminth ova with the Kato-Katz method 28 and by charcoal culture for Strongyloides sterocoralis infection; 29 two Kato-Katz slides were prepared from each sample and examined for hookworm ova within 30 mins of preparation, or examined the next day for other species. Hookworm and Schistosoma mansoni infections were classifi ed into low, medium, and high intensities according to WHO guidelines. 30 Blood samples were examined by a modifi ed Knott's method for Mansonella perstans 31 and by thick fi lm for malaria parasites. Haemoglobin was estimated by Coulter analyser (Beckman Coulter, Nyon, Switzerland). Quality control for Kato-Katz analyses was provided by the Vector Control Programme of the Ministry of Health, Uganda, and for haematology and malaria parasitology through the UK National External Quality Assessment Schemes.
Mothers' HIV serology was done by rapid test algorithm. 30 Blood was obtained from cord and at 6 weeks of age from infants of mothers with HIV for assessment of vertical HIV transmission. Plasma and whole blood cell pellet were separated by centrifugation and stored at -80°C until assays were done. For detection of HIV-1 proviral DNA in infants at 6 weeks, DNA was extracted from stored whole blood cell pellets and amplifi ed by nested PCR of three conserved viral regions, tat, gp41, and nef (webappendix p 1). For both cord and 6-week samples, plasma HIV load was measured with Bayer Versant branched DNA assay version 3.0 (Bayer, Leverkusen, Germany) or Roche Amplicor HIV-1 RNA Monitor test version 1.5 (Roche, NJ, USA).
Infants were regarded as being HIV positive if the 6-week sample had a positive DNA PCR for any of the viral regions and a viral load of 1000 copies per mL or more; for four infants, only viral load data were available, so they were used to establish HIV status. Viral load and DNA-PCR results were concordant apart from one infant (viral load 6699 copies per mL, PCR negative) who was seronegative by rapid test algorithm at age 18 months and was classifi ed as HIV negative. In infants with HIV infection, transmission was regarded as likely to have been intrauterine if the viral load in cord blood was 1000 copies per mL or more.
Statistical analysis
Analysis was done after all children were older than 15 months. Data for samples and measurements obtained at routine, 1-year visits were included if the child attended within 2 months after their fi rst birthday. Data for illness events and mortality were censored strictly at 1 year. Results for younger twins were excluded from all analyses.
On the basis of our preliminary study, 32 the planned cohort size of 2500 was expected to accrue 1860 personyears of follow-up in infancy and 1594 infants were See Online for webappendix expected to be seen at age 1 year. For either maternal treatment, assuming no interaction between treatments, this number would give 80% power to detect rate ratios of 0·82 for malaria, 0·91 for diarrhoea, and 0·76 for pneumonia, with p values of less than 0·05, assuming frequency of disease in the placebo groups to be 50 per 100 person-years for malaria, 33 190 per 100 person-years for diarrhoea, 34 and 25 per 100 person-years for pneumonia. 35 Incidence of both tuberculosis and measles was expected to be low, 18 therefore only very large diff erences in incidence would be detected. Samples from 1594 infants assessed at 1 year would detect diff erences in infant cytokine responses of 0·11 log 10 between intervention groups. 18, 32 The patients that were included in analysis for each of the primary outcomes diff ered because data for each outcome was obtained at diff erent times. For immune response at age 1 year, analysis included all children who provided a blood sample at 1 year and who had received full BCG (for cCFP analysis) or tetanus (for tetanus toxoid analysis) immunisation at Entebbe Hospital; second-born twins were excluded. For incidence of infectious diseases during infancy, analysis included all liveborn children, excluding second-born twins. For vertical HIV transmission, analysis included all children whose mothers were not receiving highly-active antiretroviral therapy, and from whom blood samples at age 6 weeks were available; second-born twins were excluded. Cytokine and antibody responses showed skewed distributions, with disproportionate numbers of zero values. Results were transformed to log 10 (concentration+1) and analysed by linear regression with bootstrapping to estimate bias-corrected accelerated confi dence intervals. 36 Regression coeffi cients were back-transformed to give geometric mean ratios. Interactions were examined with Wald tests.
For doctor-diagnosed disease incidence, time at risk began at birth and was censored at loss to follow-up, death, or age 1 year. All children with known date of birth were included in the analysis until censoring, irrespective of whether they had made a clinic visit for illness. For each disease, we calculated incidence rates for all events. Disease episodes within 14 days of an initial presentation with the same disease were regarded as part of the same episode and excluded from the analysis; time at risk was adjusted accordingly, excluding these 14-day periods from the total person-time denominator. Hazard ratios (HRs) for eff ects of treatment were calculated with Cox regression, with robust SEs to allow for within-child clustering. For community-reported illness data, a generalised-estimatingequation approach with exchangeable correlation structure was used to model eff ects of treatment on repeated binary outcomes. Odds ratios (ORs) for the eff ects of treatment on vertical HIV transmission were calculated with logistic regression.
The prevalence of asymptomatic malaria at 1 year was compared between treatment groups with logistic regression. Infant mortality per 1000 livebirths was estimated from Kaplan-Meier survival probabilities to age 1 year, and eff ects of maternal anthelmintic treatment were assessed by Cox regression. Weight-for-age, height-for-age, and weight-for-height Z scores at 1 year were derived from WHO growth standard reference scales, with igrowup macros. We examined eff ects of maternal treatment on Z scores and on haemoglobin at 1 year by linear regression.
We did two prespecifi ed subgroup analyses, examining eff ects of albendazole treatment in children of mothers with a hookworm infection, and eff ects of praziquantel treatment in children of mothers with schistosomiasis. Diff erences between subgroups were examined by fi tting interaction terms in regression models. All p values were two-sided with no adjustment made for multiple comparisons. Analyses were done with Stata 10.1.
Role of the funding source
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. AME had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
The fi gure shows the trial profi le. 2507 women were randomly assigned to treatment groups, 1309 (52%) of whom were in the second trimester of pregnancy and 1195 (48%) of whom were in the third trimester of pregnancy. The median length of time between receiving the study intervention and delivery was 87 days (IQR 54-118). Data were available for 2356 women (94%) at delivery and there were 2345 livebirths; results for 30 liveborn younger twins or triplets were excluded, which left data for follow-up of 2315 liveborn infants. Of these infants, 2092 (90%) remained in follow-up at 1 year of age, of whom 1701 (81%) attended the 1-year visit. Baseline characteristics of mothers were similar between the four groups (table 1). 37 Mothers of children who did not contribute to follow-up were, on average, younger, more likely to be pregnant for the fi rst time, have malaria or HIV infection, and have enrolled earlier during pregnancy than mothers of children who contributed to follow up (data not shown). Mothers of children who provided samples at 1 year of age were of higher socioeconomic status and less likely to reside in remote parts of the study area than were mothers of children who did not provide samples at age 1 year (data not shown).
At enrolment, 1693 (68%) of women were infected with at least one helminth species. Individual prevalences of each species were: hookworm 45%, M perstans 21%, S mansoni 18%, S stercoralis 12%, Trichuris trichiura 9%, and Ascaris lumbricoides 2%. Infections were generally mild, with 942 (85%) of hookworm infections and 297 (65%) of S mansoni infections classifi ed as light. Subgroups of 648 mothers who received albendazolematching placebo and 658 mothers who received praziquantel-matching placebo had three stool samples examined before being treated 6 weeks after delivery; in these women, the sensitivity of one stool sample compared with three stool samples was 89% for hookworm infection and 66% for schistosomiasis. 1957 mothers (78%) received at least one documented dose of tetanus immunisation during pregnancy; 1447 (74%) received all documented tetanus immun isations before the anthelmintic treatment inter vention (median 4 days [IQR 3-7] before intervention).
We noted no evidence of interaction between maternal albendazole and praziquantel treatments for any outcome (all interaction p values>0·1; webappendix pp 3-4); therefore the eff ects of each treatment were assessed independently. Results for cytokine responses at age 1 year were available for 1542 infants, of whom 1506 had received BCG immunisation at birth at Entebbe Hospital and 1015 had received all three doses of tetanus immunisation at Entebbe Hospital. The proportion of infants for whom positive responses to cCFP and tetanus toxoid were detected varied by cytokine; for cCFP, 1356 (90%) infants had positive responses to interferon-γ, 449 (30%) had positive responses to interleukin 5, 1005 (67%) had positive responses to interleukin 13, and 1316 (87%)
For more on igrowup macros see http://www.who.int/ childgrowth/software/en/ had positive responses to interleukin-10. For tetanus toxoid, 655 (65%) infants had positive responses to interferon-γ, 499 (49%) had positive responses to interleukin 5, 766 (75%) had positive responses to interleukin 13, and 498 (49%) had positive responses to interleukin 10.
Albendazole treatment of mothers was associated with a small reduction in unstimulated interleukin-10 production by their children (geometric mean ratio 0·83, 95% CI 0·70-0·98). We recorded no other overall eff ects of maternal treatment on unstimulated cytokine production. Results for eff ects on responses to stimulation were similar, irrespective of whether background cytokine production was subtracted (data not shown).
We detected no eff ects of either albendazole or praziquantel treatments on the overall antigen-specifi c response after immunisation (table 2) . However, in infants of mothers with a hookworm infection, maternal albendazole treatment was associated with a small nonsignifi cant reduction in the interferon-γ response to cCFP and with reductions in their response to tetanus toxoid for the type 2 cytokines interleukin 5 and interleukin 13 (table 3) . We recorded no signifi cant eff ect of praziquantel treatment in infants of mothers with schistosomiasis (table 3) .
We recorded no overall eff ects for either albendazole or praziquantel treatments on antibody concentrations for tetanus or measles (table 2) , nor did we detect diff erential eff ects for either albendazole or praziquantel treatment according to susceptible worm species (table 3) .
Of the 2315 liveborn children, 2083 (90%) made at least one illness-related clinic visit during infancy. The number of illness visits by children in all four treatment groups were similar (webappendix p 4). During the study period, the rate of malaria was 41 episodes per 100 personyears (95% CI 38-44), of diarrhoea 134 episodes per 100 person-years (129-139), and of pneumonia 22 episodes per 100 person-years (20) (21) (22) (23) (24) . Measles and tuberculosis were rare, with two episodes of each, so we could not assess the eff ect of maternal anthelmintic treatment on their frequency.
We noted no evidence for eff ects of either albendazole or praziquantel treatments on doctor-diagnosed malaria, diarrhoea, or pneumonia incidence (table 4). Subgroup analyses by maternal hookworm and schistosomiasis infection status showed no evidence of a diff erential eff ect of either treatment according to susceptible worm species (table 5) .
299 women tested positive for HIV at enrolment; of these, 16 were lost to follow-up before delivery, fi ve had miscarriages, and nine had stillbirths. Five women were on highly-active antiretroviral therapy; their children, and seven second-born twins were excluded from the analysis, leaving 264 infants suitable for inclusion. 6-week blood samples were available from 211 infants (80%), of whom 39 (18%) were diagnosed with HIV infection. Of infants with HIV infection, 31 had cord samples available, of which 20 (65%) showed an HIV viral load of 1000 copies per mL or more, which is consistent with intrauterine HIV transmission. We recorded no evidence for any eff ect of either albendazole (OR 0·70, 95% CI 0·35-1·42; p=0·33) or praziquantel (0·60, 0·29-1·23; p=0·17) treatment on vertical HIV transmission, although statistical power was restricted because the study was only powered to detect a large eff ect for this outcome. No 
Tetanus toxoid †
cCFP=crude culture fi ltrate proteins of Mycobacterium tuberculosis. GMR=geometric mean ratio. *cCFP cytokine responses were available for 1506 infants given BCG at Entebbe Hospital; four missing values in this analysis for infants of women with no stool result for Kato-Katz analysis. †Tetanus toxoid cytokine results were available for 1015 infants who received all three doses of tetanus toxoid; two missing values in this analysis for infants of women with no stool result for Kato-Katz analysis; one missing value for interferon-γ response to tetanus toxoid. ‡Tetanus toxoid antibody results were available for 1058 (IgG), 1057 (IgG4), and 979 (IgE) infants who received all three doses of tetanus toxoid; one missing value in this analysis for an infant of a woman with no stool result for Kato-Katz analysis. § Measles antibody results were available for 1233 infants who received measles immunisation; three missing values in this analysis for infants of women with no stool result for Kato-Katz analysis. evidence was noted for any diff erential eff ect of treatment according to susceptible worm species; ORs for the eff ect of albendazole treatment on HIV transmission were 0·77 (0·25-2·40) in mothers with hookworm infection and 0·66 (0·27-1·60) in those without hookworm infection (interaction p=0·83). We recorded similar results for praziquantel (OR 0·75, 0·18-3·14, for mothers with schistosomiasis; 0·56, 0·24-1·29 for those without schistosomiasis; interaction p=0·73). For the secondary outcome of community-reported illness data, the overall recorded prevalences of each illness collated every 14 days throughout infancy was 13% for febrile illness, 12% for diarrhoea, and 1% for presumptive pneumonia. These data were consistent with doctor-diagnosed outcomes and showed no eff ects of treatment with albendazole or praziquantel on febrile illnesses (OR 1·07, 95% CI 0·97-1·18, p=0·18; and 1·03, 0·93-1·13, 0·58), diarrhoea (1·08, 0·98-1·20, 0·13; and 0·93, 0·84-1·03, 0·18), or presumptive pneumonia (0·92, 0·65-1·31, 0·66; and 0·91, 0·64-1·30, 0·62). The prevalence of asymptomatic malaria parasitaemia at 1 year was similar between treatment groups (webappendix p 5). 81 infants in the cohort died, 44 of whom were neonates, giving a neonatal mortality rate of 19·0 per 1000 livebirths (95% CI 14·2-25·5) and an infant mortality rate of 35·7 per 1000 livebirths (28·8-44·2). Maternal anthelmintic treatment had no pronounced eff ect on mortality (webappendix p 5). Height-for-age and weightfor-age Z scores were low compared with the WHO standards; however, the weight-for-height distribution was similar. Mean haemoglobin score at age 1 year was 102 g/L (SD 14 g/L). We noted no evidence for any diff erence in mean growth indices or mean haemoglobin between children of albendazole-treated and placebotreated mothers, or between children of praziquanteltreated and placebo-treated mothers (webappendix p 5). Numbers of serious adverse events are reported elsewhere 19 and were distributed evenly between treatment groups.
Discussion
In this randomised, placebo-controlled trial, we have shown that maternal anthelmintic treatment during pregnancy can have a small eff ect on an infant's response to tetanus immunisation, but has no eff ects, either benefi cial or detrimental, on the occurrence of infectious diseases during infancy, infant mortality, or growth and anaemia outcomes at 1 year of age. One dose of albendazole was eff ective for the treatment of hookworm and A lumbricoides infections, and praziquantel was eff ective for the treatment of schistosomiasis. At delivery, the prevalence of hookworm infections had decreased to 5% in the albendazole group, and remained at 45% in the placebo group; the prevalence of S mansoni infection had decreased to 5% in the praziquantel group, and remained at 21% in the placebo group. 37 Thus we would have expected to see any noticeable eff ects of the removal of these maternal helminth infections. A possible source of imprecision is that the Kato-Katz method has suboptimum 
HR=hazard ratio. *Excludes nine women with no stool result for Kato-Katz analysis. 38, 39 In this study, the sensitivity for detecting both hookworm infection and schistosomiasis was greater when three stool samples were taken than when only one was taken. As expected, one dose of albendazole was not eff ective for treatment of S stercoralis, T trichiura, or M perstans. 37 Albendazole treatment in pregnancy was associated with reduced interleukin-5 and interleukin-13 responses to tetanus toxoid in infants of mothers with hookworm infection. These results should be interpreted with caution because of the large number of statistical tests done, but they accord with earlier fi ndings 40, 41 on eff ects of helminths on type-2 responses to tetanus immunisation in adults; by contrast with these previous studies, 40, 41 we recorded no reciprocal eff ect on interferon-γ response. Such responses will probably not change the eff ectiveness of tetanus immunisation, because this immunisation depends on the production of toxin-neutralising IgG antibodies, which was not aff ected by maternal treatment. However, the patterns recorded lend support to the hypothesis that maternal helminths promote a type-2 bias in an infant's response to unrelated antigens and that anthelmintic treatment modifi es this eff ect. These fi ndings suggest that the eff ect of anthelmintic treatment can be transmitted in utero.
Neither intervention showed any overall eff ect on response to BCG immunisation in infants. Our preliminary study 32 had suggested an unexpected positive association between maternal hookworm infection and interferon-γ responses to cCFP in infants. In the present, larger study, interferon-γ responses were higher in infants of mothers with hookworm infection, and albendazole treatment was associated with a weak reduction in interferon-γ responses in infants of women with hookworm infection. These fi ndings contrast with our initial hypothesis that maternal hookworm infection would inhibit the Th1 response and that albendazole treatment would reverse this eff ect. The absence of eff ect of praziquantel treatment was also unexpected, in view of Malhotra and colleagues' fi nding 17 that infants who are sensitised to schistosome or fi larial antigens in utero had reduced interferon-γ and increased interleukin-5 responses to neonatal BCG immunisation. However, all infants in Malhotra and colleagues' study were exposed to maternal helminth infections, and comparisons were made between those not sensitised or sensitised to helminth antigens. 17 The idea that single-dose praziquantel treatment completely removes the likelihood of fetal sensitisation to schistosome antigens might be too simplistic, because worm and egg antigens can take some time to be cleared from maternal tissues. Moreover, the killing of adult schistosomes results in release of worm antigen into the circulation and might have complex eff ects on the fetus, dependent on placental transfer of antigens or antibodies and the stage of development of the fetal immune system. 41, 42 The recorded eff ects on an infant's response to tetanus immunisation contrasted with the absence of eff ects seen for measles and BCG. A possible explanation is that tetanus immunisation given to women during pregnancy could have led to the priming of an infant's antitetanus response in utero, 42 and the profi le of the primed response could have been aff ected by concomitant exposure to a maternal helminth infection, which depended on whether or not an infant's mother received treatment with albendazole.
In keeping with the broad absence of eff ect of maternal anthelmintic treatment on an infant's response to vaccination, we recorded no eff ect of either treatment for the co-primary outcome of infectious disease incidence during infancy. A possible source of imprecision is that data for doctor-diagnosed disease incidence were obtained passively, and therefore rates are likely to have been underestimated. However, 90% of infants attended the clinic for illness at least once, and underestimation would be non-diff erential between treatment groups; therefore this imprecision is unlikely to have aff ected our fi ndings. Moreover, results from communityreported illness events (which are less likely to be underreported), and malaria parasitaemia at 1 year of age (which is independent of reporting biases) were both consistent with the recorded absence of treatment eff ect. We also detected no evidence that anthelmintic treatment aff ected vertical transmission of HIV, although power to detect an eff ect was restricted.
The only other study 43 to investigate the relation between anthelmintic treatment during pregnancy and post-neonatal outcomes, undertaken in Nepal, showed that treatment with albendazole during pregnancy was associated with a pronounced reduction in infant mortality at 6 months. We recorded no such eff ect, although the number of deaths in the cohort was small so the possibility of a reduction cannot be ruled out. The Nepal study was not randomised and recorded a 41% reduction in 6-month mortality associated with two doses of albendazole but no eff ect on infant mortality for one dose. The researchers speculated that the greater benefi t of two doses might result from prevention of reinfection between treatment and delivery, but this theory would not explain the contrast with our fi ndings, because only 5% of women who received albendazole in our study had hookworm infection at delivery. 19 Our analyses needed many statistical tests, especially for the measurement of cytokine responses to immunisation, because we aimed to assess overall response profi les rather than concentrations of only one cytokine. Consistency between all cytokine responses was expected, and can be interpreted as compelling evidence of an eff ect, compared with isolated change in an individual response. Therefore we did not increase confi dence limits or use methods that assume independence of tests to formally adjust p values. In the event, very few outcomes showed any evidence of association at a p value less than 0·05 so absence of adjustment for multiplicity is unlikely to have aff ected the interpretation of our results.
A strength of this study was the randomised intervention design; eff ects of helminth infections reported in observational studies could have been aff ected by confounding factors. Our fi ndings do not show that exposure to maternal helminth infections in utero has no important eff ect on the development of the fetal immune system. Some observational studies 16, 17 do suggest such an eff ect. Rather, our fi ndings suggest that one eff ective anthelmintic intervention given in the second or third trimester of pregnancy is insuffi cient to alter any eff ect of maternal worms on vaccine and infectious disease outcomes in infancy. This study examined only eff ects of maternal anthelmintic treatment on vaccine responses and disease incidence in newborn children. Further studies are needed to assess the eff ects of anthelmintic treatment on these outcomes in the individual who receives the treatment.
Our results are generalisable to areas with high prevalence but low intensity of helminth infection in young adults, which is a common pattern in areas that are endemic for helminth infection. Findings might diff er in populations with higher infection intensities. These results suggest that, in settings such as Entebbe Municipality and Katabi subcounty, single-dose anthelmintic treatment during pregnancy has no benefi t for an infant's response to immunisation, or for their health and development.
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